Minnesota Administrative Rules

4605.7040 DISEASE AND REPORTS; CLINICAL MATERIALS SUBMISSIONS.

Persons required to report under this chapter shall report to the commissioner cases, suspected cases, carriers, and deaths due to the following diseases and infectious agents. When submission of clinical materials is required under this part, submissions shall be made to the Minnesota Department of Health, Public Health Laboratory.

A.

Diseases reportable immediately by telephone to the commissioner:

(1)

anthrax (Bacillus anthracis). Submit clinical materials;

(2)

botulism (Clostridium botulinum);

(3)

brucellosis (Brucella abortus, Brucella canis, Brucella melitensis, Brucella suis). Submit clinical materials;

(4)

cholera (Vibrio cholerae). Submit clinical materials;

(5)

diphtheria (Corynebacterium diphtheriae). Submit clinical materials;

(6)

free-living amebic infection (including at least: Acanthamoeba spp., Naegleria fowleri, Balamuthia spp., Sappinia spp). Submit clinical materials;

(7)

glanders (Burkholderia mallei). Submit clinical materials;

(8)

hemolytic uremic syndrome. Submit clinical materials;

(9)

measles (rubeola). Submit clinical materials;

(10)

melioidosis (Burkholderia pseudomallei). Submit clinical materials;

(11)

meningococcal disease (Neisseria meningitidis) (all invasive disease). Submit clinical materials;

(12)

Middle East Respiratory Syndrome (MERS). Submit clinical materials;

(13)

orthopox virus. Submit clinical materials;

(14)

plague (Yersinia pestis). Submit clinical materials;

(15)

poliomyelitis. Submit clinical materials;

(16)

Q fever (Coxiella burnetii). Submit clinical materials;

(17)

rabies (animal and human cases and suspected cases);

(18)

rubella and congenital rubella syndrome. Submit clinical materials;

(19)

severe acute respiratory syndrome (SARS). Submit clinical materials;

(20)

smallpox (variola). Submit clinical materials;

(21)

tularemia (Francisella tularensis). Submit clinical materials; and

(22)

viral hemorrhagic fever (including but not limited to Ebola virus disease and Lassa fever). Submit clinical materials.

B.

Diseases reportable within one working day:

(1)

anaplasmosis (Anaplasma phagocytophilum);

(2)

arboviral disease, including, but not limited to, La Crosse encephalitis, Eastern equine encephalitis, Western equine encephalitis, St. Louis encephalitis, West Nile virus disease, Powassan virus disease, and Jamestown Canyon virus disease;

(3)

babesiosis (Babesia spp.);

(4)

blastomycosis (Blastomyces dermatitidis or B. gilchristii);

(5)

bluegreen algae (Cyanobacteria) and cyanotoxin poisoning;

(6)

campylobacteriosis (Campylobacter spp.). Submit clinical materials;

(7)

Candida auris (C. auris). Submit clinical materials;

(8)

Capnocytophaga canimorsus;

(9)

carbapenem-resistant Acinetobacter baumannii (CRAB). Submit clinical materials;

(10)

carbapenem-resistant Enterobacterales (CRE). Submit clinical materials;

(11)

carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa (CP-CRPA). Submit clinical materials;

(12)

cat scratch disease (infection caused by Bartonella species);

(13)

chancroid (Haemophilus ducreyi);

(14)

chikungunya disease;

(15)

Chlamydia trachomatis infections, (including serotypes L1, L2, and L3);

(16)

coccidioidomycosis;

(17)

cytomegalovirus (congenital - positive laboratory results collected from infants less than or equal to 90 days of age, or from amniotic fluid);

(18)

Cronobacter sakazakii in infants under one year of age. Submit clinical materials;

(19)

cryptosporidiosis (Cryptosporidium spp.). Submit clinical materials;

(20)

cyclosporiasis (Cyclospora spp.). Submit clinical materials;

(21)

dengue virus infection;

(22)

ehrlichiosis (Ehrlichia spp.);

(23)

encephalitis (caused by viral agents);

(24)

enteric Escherichia coli infection (E. coli O157:H7, other Shiga toxin-producing (enterohemorrhagic) E. coli, enteropathogenic E. coli, enteroinvasive E. coli, enteroaggregative E. coli, enterotoxigenic E. coli, or other pathogenic E. coli). Submit clinical materials;

(25)

giardiasis (Giardia duodenalis);

(26)

gonorrhea (Neisseria gonorrhoeae infections). Submit clinical materials isolated from a normally sterile site and upon request;

(27)

Haemophilus influenzae disease (all invasive disease). Submit clinical materials;

(28)

hantavirus infection;

(29)

hard tick relapsing fever (Borrelia miyamotoi);

(30)

hepatitis (all primary viral types including A, B, C, D, and E). Submit clinical materials for hepatitis A upon request;

(31)

histoplasmosis (Histoplasma capsulatum);

(32)

human immunodeficiency virus (HIV) infection, including acquired immunodeficiency syndrome (AIDS);

(33)

influenza (unusual case incidence, critical illness, or laboratory confirmed cases). Submit clinical materials;

(34)

Kawasaki disease;

(35)

Kingella spp. (invasive only). Submit clinical materials;

(36)

legionellosis (Legionella spp.). Submit clinical materials;

(37)

leprosy (Hansen's disease) (Mycobacterium leprae);

(38)

leptospirosis (Leptospira interrogans);

(39)

listeriosis (Listeria monocytogenes). Submit clinical materials;

(40)

Lyme disease (Borrelia burgdorferi and other Borrelia spp.);

(41)

malaria (Plasmodium spp.);

(42)

meningitis (caused by viral agents);

(43)

multisystem inflammatory syndrome associated with SARS-CoV-2 infection, including in children (MIS-C) and adults (MIS-A);

(44)

mumps. Submit clinical materials;

(45)

neonatal sepsis (bacteria isolated from a sterile site, excluding coagulase-negative Staphylococcus) less than seven days after birth. Submit clinical materials;

(46)

pertussis (Bordetella pertussis). Submit clinical materials;

(47)

psittacosis (Chlamydophila psittaci);

(48)

rat-bite fever (Streptobacillus moniliformis);

(49)

salmonellosis, including typhoid (Salmonella spp.). Submit clinical materials;

(50)

SARS-CoV-2 infection (COVID-19) (unusual case incidence, critical illness, or laboratory confirmed cases). Submit clinical materials;

(51)

shigellosis (Shigella spp.). Submit clinical materials;

(52)

Spotted fever rickettsiosis (Rickettsia spp. infections, including Rocky Mountain spotted fever);

(53)

Staphylococcus aureus (only vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-resistant Staphylococcus aureus (VRSA), and death or critical illness due to community-associated Staphylococcus aureus in a previously healthy individual). Submit clinical materials;

(54)

streptococcal disease (all invasive disease caused by Groups A and B streptococci and S. pneumoniae [including urine antigen laboratory-confirmed pneumonia]). Except for urine, submit clinical materials;

(55)

syphilis (Treponema pallidum);

(56)

tetanus (Clostridium tetani);

(57)

toxic shock syndrome. Submit clinical materials;

(58)

toxoplasmosis (Toxoplasma gondii);

(59)

transmissible spongiform encephalopathy;

(60)

trichinosis (Trichinella spiralis);

(61)

tuberculosis (Mycobacterium tuberculosis complex) (pulmonary or extrapulmonary sites of disease, including clinically diagnosed disease). Latent tuberculosis infection is not reportable. Submit clinical materials;

(62)

typhus (Rickettsia spp.);

(63)

varicella (chickenpox). Submit clinical materials;

(64)

Vibrio spp. Submit clinical materials;

(65)

yellow fever;

(66)

yersiniosis, enteric (Yersinia spp.). Submit clinical materials;

(67)

zika virus disease; and

(68)

zoster (shingles) (all cases <18 years old; other unusual case incidence or complications regardless of age). Submit clinical materials.

Statutory Authority:

MS s 144.05; 144.072; 144.0742; 144.12; 144.122

History:

9 SR 2584; 20 SR 858; 30 SR 247; 41 SR 829; 43 SR 415; 49 SR 329

Published Electronically:

October 4, 2024